Prelude Capital Management’s Inozyme Pharma INZY Stock Holding History

Prelude Capital Management’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-84,648	Closed	-$339K	–	1265
2025 Q2	$339K	Buy	+84,648	New	+$210K	0.03%	565
2024 Q2	–	Sell	-62,445	Closed	-$478K	–	1358
2024 Q1	$478K	Buy	+62,445	New	+$343K	0.03%	656

Prelude Capital Management's INZY Position: Q3 2025 in Review

Prelude Capital Management sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 84,648 shares — an estimated $339K sold.

Prelude Capital Management first reported a position in INZY in Q1 2024 and held it in 2 quarters. The position peaked at $478K in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

Prelude Capital Management reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 84,648 Inozyme Pharma shares in Q3 2025, an estimated $339K.
Prelude Capital Management first reported a position in Inozyme Pharma in Q1 2024 and held it in 2 quarters.
Prelude Capital Management's Inozyme Pharma position peaked at $478K in Q1 2024.
0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.